133 related articles for article (PubMed ID: 12434120)
1. CD 34 expression in chronic and neoplastic liver diseases.
Di Carlo I; Fraggetta F; Lombardo R; Azzarello G; Vasquez E; Puleo S
Panminerva Med; 2002 Dec; 44(4):365-7. PubMed ID: 12434120
[TBL] [Abstract][Full Text] [Related]
2. Immunoreactivity of sinusoids in hepatocellular carcinoma. An immunohistochemical study using lectin UEA-1 and antibodies against endothelial markers, including CD34.
Ruck P; Xiao JC; Kaiserling E
Arch Pathol Lab Med; 1995 Feb; 119(2):173-8. PubMed ID: 7531428
[TBL] [Abstract][Full Text] [Related]
3. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
4. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies?
de Boer WB; Segal A; Frost FA; Sterrett GF
Cancer; 2000 Oct; 90(5):273-8. PubMed ID: 11038423
[TBL] [Abstract][Full Text] [Related]
5. Histopathological and immunohistochemical analysis of adenomatous hyperplasia and hepatocellular carcinoma: cellularity, thickness of cell cord, and Ki-67 proliferative activity.
Than KW; Okayasu I; Akashi T
Bull Tokyo Med Dent Univ; 1995 Jun; 42(2):67-81. PubMed ID: 7540960
[TBL] [Abstract][Full Text] [Related]
6. [Capillarisation of hepatic sinusoids in chronic hepatitis--immunohistochemical evaluation].
Grigoraş A; Cotuţiu C; Grigorescu EO
Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):505-8. PubMed ID: 21495357
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?
Kara B; Doran F; Kara IO; Akkiz H; Sandikci M
Int J Clin Pract; 2008 Aug; 62(8):1206-11. PubMed ID: 18284441
[TBL] [Abstract][Full Text] [Related]
8. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
9. Expression of sialylated Lewis(x) antigen in chronic and neoplastic liver diseases.
Jagirdar J; Thung SN; Shah KD; Nudelman E; Singhal A; Paronetto F
Arch Pathol Lab Med; 1992 Jun; 116(6):643-8. PubMed ID: 1352099
[TBL] [Abstract][Full Text] [Related]
10. Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma.
Morinaga S; Tarao K; Yamamoto Y; Nakamura Y; Rino Y; Miyakawa K; Ohkawa S; Akaike M; Sugimasa Y; Takemiya S
J Gastroenterol Hepatol; 2007 Aug; 22(8):1249-55. PubMed ID: 17688665
[TBL] [Abstract][Full Text] [Related]
11. Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions.
Heukamp LC; Fischer HP; Schirmacher P; Chen X; Breuhahn K; Nicolay C; Büttner R; Gütgemann I
Histopathology; 2006 Sep; 49(3):242-7. PubMed ID: 16918970
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma, adenoma, and focal nodular hyperplasia. Comparative histopathologic study with immunohistochemical parameters.
Koelma IA; Nap M; Huitema S; Krom RA; Houthoff HJ
Arch Pathol Lab Med; 1986 Nov; 110(11):1035-40. PubMed ID: 2430547
[TBL] [Abstract][Full Text] [Related]
13. Expression of membrane cofactor protein (MCP, CD46) in human liver diseases.
Kinugasa N; Higashi T; Nouso K; Nakatsukasa H; Kobayashi Y; Ishizaki M; Toshikuni N; Yoshida K; Uematsu S; Tsuji T
Br J Cancer; 1999 Aug; 80(11):1820-5. PubMed ID: 10468303
[TBL] [Abstract][Full Text] [Related]
14. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.
Masaki T; Tokuda M; Yoshida S; Nakai S; Morishita A; Uchida N; Funaki T; Kita Y; Funakoshi F; Nonomura T; Himoto T; Deguchi A; Kimura Y; Izuishi K; Wakabayashi H; Usuki H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
Int J Oncol; 2005 Mar; 26(3):661-71. PubMed ID: 15703821
[TBL] [Abstract][Full Text] [Related]
15. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
[TBL] [Abstract][Full Text] [Related]
16. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
[TBL] [Abstract][Full Text] [Related]
17. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
Tátrai P; Somorácz A; Batmunkh E; Schirmacher P; Kiss A; Schaff Z; Nagy P; Kovalszky I
Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
[TBL] [Abstract][Full Text] [Related]
18. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
[TBL] [Abstract][Full Text] [Related]
19. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
20. [Expression of GST-pi and HBV infection in hepatocellular carcinoma].
Shen LJ; Zhang ZJ; Zhang HX; Yang WB; Huang R
Ai Zheng; 2002 Jan; 21(1):29-32. PubMed ID: 12500393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
